Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 19;187(4):593-605.
doi: 10.1530/EJE-22-0440. Print 2022 Oct 1.

Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients

Pia Burman  1 , Jacqueline Trouillas  2 , Marco Losa  3 , Ann McCormack  4 , Stephan Petersenn  5 , Vera Popovic  6 , Marily Theodoropoulou  7 , Gerald Raverot  8 , Olaf M Dekkers  9 ; ESE survey collaborators †
Collaborators, Affiliations

Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients

Pia Burman et al. Eur J Endocrinol. .

Abstract

Objective: To describe clinical and pathological characteristics and treatment outcomes in a large cohort of aggressive pituitary tumours (APT)/pituitary carcinomas (PC).

Design: Electronic survey August 2020-May 2021.

Results: 96% of 171 (121 APT, 50 PC), initially presented as macro/giant tumours, 6 were microadenomas (5 corticotroph). Ninety-seven tumours, initially considered clinically benign, demonstrated aggressive behaviour after 5.5 years (IQR: 2.8-12). Of the patients, 63% were men. Adrenocorticotrophic hormone (ACTH)-secreting tumours constituted 30% of the APT/PC, and the gonadotroph subtypes were under-represented. Five out of 13 silent corticotroph tumours and 2/6 silent somatotroph tumours became secreting. Metastases were observed after median 6.3 years (IQR 3.7-12.1) from diagnosis. At the first surgery, the Ki67 index was ≥3% in 74/93 (80%) and ≥10% in 38/93 (41%) tumours. An absolute increase of Ki67 ≥ 10% after median of 6 years from the first surgery occurred in 18/49 examined tumours. Tumours with an aggressive course from outset had higher Ki67, mitotic counts, and p53. Temozolomide treatment in 156/171 patients resulted in complete response in 9.6%, partial response in 30.1%, stable disease in 28.1%, and progressive disease in 32.2% of the patients. Treatment with bevacizumab, immune checkpoint inhibitors, and peptide receptor radionuclide therapy resulted in partial regression in 1/10, 1/6, and 3/11, respectively. Median survival in APT and PC was 17.2 and 11.3 years, respectively. Tumours with Ki67 ≥ 10% and ACTH-secretion were associated with worse prognosis.

Conclusion: APT/PCs exhibit a wide and challenging spectrum of behaviour. Temozolomide is the first-line chemotherapy, and other oncological therapies are emerging. Treatment response continues to be difficult to predict with currently studied biomarkers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Hormone secretion and gender reported in 168 aggressive pituitary tumours/carcinomas. Male gender was predominant among tumours secreting PRL and ACTH, and in non-functioning tumours (e.g. clinically silent tumours regardless of hormone staining at immunohistochemistry); number of cases in columns.
Figure 2
Figure 2
Tumour size at initial presentation with respect to the main hormone secreted in 165 patients with APT/PC (information in hormone secretion or tumour size missing in 6).
Figure 3
Figure 3
Histogram showing the distribution of Ki67 values at first surgery for aggressive pituitary tumours (left panel) and pituitary carcinomas (right panel).
Figure 4
Figure 4
Kaplan–Meier curve showing time from diagnosis of the pituitary tumour to detection of metastasis in 48 patients with pituitary carcinoma.
Figure 5
Figure 5
Kaplan–Meier survival curve showing overall survival from diagnosis in a cohort of 170 patients with APT/PC.
Figure 6
Figure 6
Kaplan–Meier survival curve showing overall survival in APT/PC with respect to tumoural Ki67 indices at the first surgery (A) and hormone secretion at diagnosis (B).
See this image and copyright information in PMC

References

    1. Roncaroli F, Kovacs K, Lloyd RV, Matsuno A, Righi A. Pituitary carcinoma. In WHO Classification of Tumours of Endocrine Organs, Chapter 1, pp. 41–44. Eds Lloyd RV, Osamura RY, Klöpel G, Rosai J. Lyon, France: Tumours of Pituitary Gland,IARC, 2017.
    1. McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, Burman P. & ESE survey collaborators. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. European Journal of Endocrinology 2018178265–276. (10.1530/EJE-17-0933) - DOI - PubMed
    1. Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, Trouillas J, Dekkers OM. The European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. European Journal of Endocrinology 2018178G1–G24. (10.1530/EJE-17-0796) - DOI - PubMed
    1. Reincke M, Albani A, Assie G, Bancos I, Brue T, Buchfelder M, Chabre O, Ceccato F, Daniele A, Detomas M.et al. Corticotroph tumor progression after bilateral adrenalectomy (Nelson’s syndrome): systematic review and expert consensus recommendations. European Journal of Endocrinology 2021184P1–P16. (10.1530/EJE-20-1088) - DOI - PMC - PubMed
    1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U.et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine 2005352987–996. (10.1056/NEJMoa043330) - DOI - PubMed

MeSH terms